Navigation Links
World Anticoagulants Market to Exceed $12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Date:10/30/2008

Driven by patent expiries, development of novel therapeutics, and the rapidly aging population, the world market for anticoagulants is projected to exceed $12 billion by 2015. With just two therapy classes - vitamin K antagonist and heparin injectables, dominating the market, there exist enormous opportunities and interest in developing advanced, patient friendly anticoagulants.

San Jose, CA (PRWEB) October 30, 2008 -- The unmet medical needs of available anticoagulants offer ample scope for development in the world anticoagulants market. Continuous research and development is expected to result in novel therapies with superior therapeutic efficiency, and minimum side effects. These advanced therapeutics offer promising market prospects. Exanta, for instance, represents a cutting edge direct thrombin inhibitor that flaunts the potential to kindle demand patterns, dethrone warfarin's dominance, and challenge the supremacy of low molecular weight heparins. Identification of new indications for existing, and emerging therapies is expected to help open up brighter prospects for further growth.

Factor Xa inhibitors (oral and injectable) and direct thrombin inhibitors (oral and injectable) are among the new class of thrombin antagonists that are being evaluated for both existing as well as newer indications. Development of products for specific market niches, like, anticoagulation therapies for ischemic stroke, is additionally expected to result in expanded opportunities. Patent expiries of drugs like "Coumadin" offer a lucrative business case for generic drug manufacturers. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.

The United States dominates the world anticoagulants market, with a share of nearly 50%, as stated by Global Industry Analysts, Inc. Strong double digit growth is expected to stem from the injectable anticoagulants market, with the United States setting the pace of growth with projected CAGR in excess of 15.1% over the period of 2000 through 2010. Market for injectable anticoagulants is dominated by low molecular weight heparin (LMWH). Strong growth in LMWH market is expected to push sales of injectable anticoagulants to US$6.6 billion by 2010. Japanese oral anticoagulants market is estimated to be worth US$38.3 million. In Europe, France represents the largest market with a 23.8% share.

Major market participants profiled include AstraZeneca PLC, Barr Laboratories Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi-Aventis.

The report titled "Anticoagulants: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, drivers, issues, challenges, and research and development activities. Richly annotated with authoritative, and unbiased commentaries, and hard-to-find statistical facts, the report provides unequivocal views on future potential while throwing light on the prevailing climate in key regional markets. Product markets analyzed in the report include Oral, and Injectable (Unfractionated Heparin, and Low Molecular Weight Heparin). Latent demand patterns in product markets are quantified across major geographic market verticals including the United States, Japan, France, Germany, United Kingdom, Italy, and Spain, among others for the period 2000-2015. Also provided in the report is an enumeration of recent mergers, acquisitions, and other strategic industry activities.

For more details about this research report, please visit
http://www.strategyr.com/Anticoagulants_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/anticoagulants/injectable_oral/prweb1542674.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Repair and healing of osteoporotic fractures a focus of upcoming IOF World Congress on Osteoporosis
2. Considering Revision Surgery? Board Certified Plastic Surgeon and Washington DC-based Dr. Mark E. Richards Pioneers Facelift Revisions Attracting Patients Worldwide
3. WorldHeart Announces Effectiveness of Reverse Stock Split
4. Our cheatin brain: The brains clever way of showing us the world as a whole
5. Several US Children Among Worldwide Heroes for Inspirational Fundraising Efforts with Celine Dion
6. World Biochips Market to Reach $3.4 billion by 2012, According to New Report by Global Industry Analysts, Inc.
7. University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day
8. National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day
9. The Wireless World: Untethered Opportunities
10. This Holiday Season, Give a Gift that Does a World of Good
11. HTH Worldwide Unveils First Digital Healthcare Card
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
World Anticoagulants Market to Exceed $12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
(Date:12/8/2016)... ... 2016 , ... California Senate Bill (SB) 863, signed into law in 2012, ... and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a ... study, medical payments per claim in California decreased 4 percent in 2013 and then ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne ... offices headquartered in Hamilton County, is embarking on a charity drive with the ... finding new homes for orphaned or neglected senior dogs in the Cincinnati region, ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial consulting services to residential and commercial clients in the northern Alabama ... support for Nobis Works. , Since 1977, Nobis Works has built a network ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting ... MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone in ... it’s needed. , A 2’ x 4’ model features four modes: reading, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (“Presence”) for a purchase price of approximately $17.4 million (net of the ... revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- A Small Business Innovative Research (SBIR) grant has ... to Phoenix -based NeuroEM Therapeutics, Inc. ... will seek to determine an optimal set of treatment ... to treat Alzheimer,s Disease. The grant will also investigate ... other neurologic disorders such as Parkinson,s Disease and PTSD. ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 8, 2016 According to ... by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), ... Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global ... has witnessed healthy growth during the last decade, ... of 4.3% between 2016 and 2021 to reach ...
Breaking Medicine Technology: